Steroid resistance in severe asthma: Current mechanisms and future treatment

Current Pharmaceutical Design

Volumn 17, Issue 7, 2011, Pages 674-684

  Durham, A ^a   Adcock, I M ^a   Tliba, O ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Glucocorticoid receptor; MAPK; Oxidative stress; Severe asthma

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXAMETHASONE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; STEROID;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLUSTER ANALYSIS; CYTOPLASM; DRUG BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; EPIGENETICS; HUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG RESISTANCE; FORECASTING; GLUCOCORTICOIDS; HUMANS; RECEPTORS, GLUCOCORTICOID; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; STEROIDS;

EID: 79954543523     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795428984     Document Type: Article

References (95)

1. Holgate ST, Arshad HS, Roberts GC, Howarth PH, Thurner P, Davies DE. A new look at the pathogenesis of asthma. Clin Sci (Lond) 2010; 118(7): 439-50.
2. Lai HY, Rogers DF. Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy. Curr Opin Allergy Clin Immunol 2010; 10(1): 67-76.
3. Moore WC, Meyers DA, Wenzel SE, et al. Identification of Asthma Phenotypes using Cluster Analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2009.
4. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104(40): 15858-63.
5. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360(10): 973-84.
6. Jackson M. Asthma: The Biography. Oxford University Press; 2009.
7. Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 2009.
8. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372(9643): 1073-87.
9. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest 2008; 134(2): 394-401.
10. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373(9678): 1905-17.
11. Barnes PJ. New therapies for asthma: is there any progress? Trends Pharmacol Sci 2010; 31(7): 335-43.
12. Beck IM, Vanden BW, Vermeulen L, Yamamoto KR, Haegeman G, De BK. Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr Rev 2009; 30(7): 830-82.
13. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006; 117(3): 522-43.
14. Hew M, Chung KF. Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology. Intern Med J 2010; 40(5): 323-34.
15. Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta] and glucocorticoid resistance. Ann N Y Acad Sci 2006; 1069: 1-9.
16. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005; 353(16): 1711-23.
17. Kino T, Su YA, Chrousos GP. Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Cell Mol Life Sci 2009; 66(21): 3435-48.
18. Boyault C, Sadoul K, Pabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007; 26(37): 5468-76.
19. Rajapandi T, Greene LE, Eisenberg E. The molecular chaperones Hsp90 and Hsc70 are both necessary and sufficient to activate hormone binding by glucocorticoid receptor. J Biol Chem 2000; 275(29): 22597-604.
20. Weigel NL, Moore NL. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 2007; 21(10): 2311-9.
21. Bhavsar P, Khorasani N, Hew M, Johnson M, Chung KF. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J 2009.
22. D'Elia M, Patenaude J, Dupras C, Bernier J. T cells from burninjured mice demonstrate a loss of sensitivity to glucocorticoids. Am J Physiol Endocrinol Metab 2010; 299(2): E299-307.
23. Goleva E, Li LB, Leung DY. IFN-gamma reverses IL-2- and IL-4- mediated T-cell steroid resistance. Am J Respir Cell Mol Biol 2009; 40(2): 223-30.
24. Kent LM, Smyth LJ, Plumb J, et al. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2- methylphenyl)-7-oxo-7,8-dihy dropyrido[2,3-d] pyrimidin-2- yl]amino}ethyl)guanidine (SB706504). J Pharmacol Exp Ther 2009; 328(2): 458-68.
25. Li LB, Goleva E, Hall CF, Ou LS, Leung DY. Superantigeninduced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK] pathway. J Allergy Clin Immunol 2004; 114(5): 1059-69.
26. Tsitoura DC, Rothman PB. Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells. J Clin Invest 2004; 113(4): 619-27.
27. Zhang Y, Leung DY, Nordeen SK, Goleva E. Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor dephosphorylation. J Biol Chem 2009; 284(36): 24542-52.
28. Paul-Clark MJ, Roviezzo F, Flower RJ, et al. Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol 2003; 171(6): 3245-52.
29. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28(1): 219-42.
30. Matthews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 2004; 113(6): 1100-8.
31. Okamoto K, Tanaka H, Ogawa H, et al. Redox-dependent regulation of nuclear import of the glucocorticoid receptor. J Biol Chem 1999; 274(15): 10363-71.
32. Maneechotesuwan K, Yao X, Ito K, et al. Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med 2009; 6(5): e1000076.
33. Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005; 172(6): 704-12.
34. Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001; 79(4): 376-84.
35. So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR. Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 2007; 3(6): e94.
36. Leung TH, Hoffmann A, Baltimore D. One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimers. Cell 2004; 118(4): 453-64.
37. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009; 324(5925): 407-10.
38. So AY, Cooper SB, Feldman BJ, Manuchehri M, Yamamoto KR. Conservation analysis predicts in vivo occupancy of glucocorticoid receptor-binding sequences at glucocorticoid-induced genes. Proc Natl Acad Sci USA 2008; 105(15): 5745-9.
39. Luecke HF, Yamamoto KR. The glucocorticoid receptor blocks PTEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes Dev 2005; 19(9): 1116-27.
40. Bhavsar P, Hew M, Khorasani N, et al. Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared to non-severe asthma. Thorax 2008; 63(9): 784-90.
41. Tchen CR, Martins JRS, Paktiawal N, Perelli R, Saklatvala J, Clark AR. Glucocorticoid Regulation of Mouse and Human Dual Specificity Phosphatase 1 (DUSP1] Genes. J Biol Chem 2010; 285(4): 2642-52.
42. Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006; 116(1): 146-55.
43. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8(1): 49-62.
44. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2- mediated deacetylation of the glucocorticoid receptor enables NFkappaB suppression. J Exp Med 2006; 203(1): 7-13.
45. Adcock IM, Ford PA, Bhavsar P, Ahmad T, Chung KF. Steroid resistance in asthma: mechanisms and treatment options. Curr Allergy Asthma Rep 2008; 8(2): 171-8.
46. Roth M, Black JL. Transcription factors in asthma: are transcription factors a new target for asthma therapy? Curr Drug Targets 2006; 7(5): 589-95.
47. Loke TK, Mallett KH, Ratoff J, et al. Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoidresistant asthmatic patients. J Allergy Clin Immunol 2006; 118(2): 368-75.
48. Tudhope SJ, Catley MC, Fenwick PS, et al. The role of IkappaB kinase 2, but not activation of NF-kappaB, in the release of CXCR3 ligands from IFN-gamma-stimulated human bronchial epithelial cells. J Immunol 2007; 179(9): 6237-45.
49. Tliba O, Damera G, Banerjee A, et al. Cytokines induce an early steroid resistance in airway smooth muscle cells: novel role of interferon regulatory factor-1. Am J Respir Cell Mol Biol 2008; 38(4): 463-72.
50. Bhandare R, Damera G, Banerjee A, et al. Glucocorticoid receptor interacting protein-1 restores glucocorticoid responsiveness in steroid-resistant airway structural cells. Am J Respir Cell Mol Biol 2010; 42(1): 9-15.
51. Ronacher K, Hadley K, Avenant C, et al. Ligand-selective transactivation and transrepression via the glucocorticoid receptor: Role of cofactor interaction. Molecular and Cellular Endocrinology 2009; 299(2): 219-31.
52. Su RC, Becker AB, Kozyrskyj AL, Hayglass KT. Altered epigenetic regulation and increasing severity of bronchial hyperresponsiveness in atopic asthmatic children. J Allergy Clin Immunol 2009; 124(5): 1116-8.
53. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352(19): 1967-76.
54. Osoata GO, Yamamura S, Ito M, et al. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem Biophys Res Commun 2009; 384(3): 366-71.
55. Nott A, Watson PM, Robinson JD, Crepaldi L, Riccio A. SNitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature 2008; 455(7211): 411-5.
56. Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 2009; 179(7): 542-8.
57. To Y, Ito K, Kizawa Y, et al. Targeting Phosphoinositide-3-kinase- {delta} with Theophylline Reverses Corticosteroid Insensitivity COPD. Am J Respir Crit Care Med 2010.
58. Li B, Carey M, Workman JL. The Role of Chromatin during Transcription. Cell 2007; 128(4): 707-19.
59. Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008; 40(7): 897-903.
60. Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009; 138(5): 1019-31.
61. Roh TY, Cuddapah S, Cui K, Zhao K. The genomic landscape of histone modifications in human T cells. Proc Natl Acad Sci USA 2006; 103(43): 15782-7.
62. Heintzman ND, Hon GC, Hawkins RD, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009; 459(7243): 108-12.
63. Adcock IM, Ford P, Ito K, Barnes PJ. Epigenetics and airways disease. Respir Res 2006; 7: 21.
64. Bhavsar P, Ahmad T, Adcock IM. The role of histone deacetylases in asthma and allergic diseases. J Allergy Clin Immunol 2008; 121(3): 580-4.
65. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26(9): 1351-6.
66. Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006; 20(20): 2871-86.
67. Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006; 174(2): 134-41.
68. Bergeron C, Fukakusa M, Olivenstein R, et al. Increased glucocorticoid receptor-beta expression, but not decreased histone deacetylase 2, in severe asthma. J Allergy Clin Immunol 2006; 117(3): 703-5.
69. Barnes PJ. Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6(8): 693-6.
70. Bartling TR, Drumm ML. Loss of CFTR results in reduction of histone deacetylase 2 in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009; 297(1): L35-L43.
71. Li LB, Leung DY, Martin RJ, Goleva E. Inhibition of Histone Deacetylase 2 Expression by Elevated Glucocorticoid Receptor Beta in Steroid Resistant Asthma. Am J Respir Crit Care Med 2010.
72. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010; 137(6): 1338-44.
73. Jee YK, Gilmour J, Kelly A, et al. Repression of interleukin-5 transcription by the glucocorticoid receptor targets GATA3 signaling and involves histone deacetylase recruitment. J Biol Chem 2005; 280(24): 23243-50.
74. Hong W, Baniahmad A, Li J, Chang C, Gao W, Liu Y. Bag-1M inhibits the transactivation of the glucocorticoid receptor via recruitment of corepressors. FEBS Lett 2009; 583(15): 2451-6.
75. Amat R, Solanes G, Giralt M, Villarroya F. SIRT1 Is Involved in Glucocorticoid-mediated Control of Uncoupling Protein-3 Gene Transcription. J Biol Chem 2007; 282(47): 34066-76.
76. Islam KN, Mendelson CR. Glucocorticoid/glucocorticoid receptor inhibition of surfactant protein-A (SP-A] gene expression in lung type II cells is mediated by repressive changes in histone modification at the SP-A promoter. Mol Endocrinol 2008; 22(3): 585-96.
77. Li LB, Leung DY, Strand MJ, Goleva E. ATF2 impairs glucocorticoid receptor-mediated transactivation in human CD8+ T cells. Blood 2007; 110(5): 1570-7.
78. Chrousos GP, Kino T. Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci STKE 2005; 2005(304): e48.
79. Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 2005; 15(11): 565-7.
80. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18(5): 601-7.
81. Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 2005; 25(8): 2873-84.
82. Creed TJ, Probert CS, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006; 23(10): 1435-42.
83. Hurley DM, Accili D, Stratakis CA, et al. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 1991; 87(2): 680-6.
84. Vingerhoeds AC, Thijssen JH, Schwarz F. Spontaneous hypercortisolism without Cushing's syndrome. J Clin Endocrinol Metab 1976; 43(5): 1128-33.
85. Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metab 2008; 93(5): 1563-72.
86. Huizenga NA, Koper JW, de Lange P, et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998; 83(1): 144-51.
87. Kino T, Stauber RH, Resau JH, Pavlakis GN, Chrousos GP. Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking. J Clin Endocrinol Metab 2001; 86(11): 5600-8.
88. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360(10): 985-93.
89. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370(9596): 1422-31.
90. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, doubleblind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179(7): 549-58.
91. Goleva E, Hauk PJ, Hall CF, et al. Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages. J Allergy Clin Immunol 2008; 122(3): 550-9.
92. Bellattato C, Adcock IM, Ito K, et al. Rhinovirus infection reduces glucocorticoid receptor nuclear translocation in airway epithelial cells. Eur Respir J 2003; 22(Suppl): 565S.
93. Garn H, Mittermann I, Valenta R, Renz H. Autosensitization as a pathomechanism in asthma. Ann N Y Acad Sci 2007; 1107: 417-25.
94. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360(23): 2445-54.
95. Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465(7300): 937-41.